News Focus
News Focus
Followers 19
Posts 817
Boards Moderated 0
Alias Born 12/12/2016

Re: sokol post# 120893

Wednesday, 09/20/2017 12:21:34 PM

Wednesday, September 20, 2017 12:21:34 PM

Post# of 517725
Excellent points, thank you, and couple the fact that he's making disclosed insider purchases WITH THE FACT that they've made it clear in the August SEC filing that they are moving forward with a new Ph2/3 trial for Alzheimer's, and it would even more-so be considered potentially misleading IF the extension trial data was poor/disappointing to date.

Dr M has previously stated that they've designed the trials to fail quickly; for compassionate considerations of the participants and caregivers I believe.

Would he press on to a confirmatory ph2/3 with hundreds of participants IF extension data was poor/disappointing?

GLTY

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News